Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 124

1.

Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer.

Arcolia V, Journe F, Renaud F, Leteurtre E, Gabius HJ, Remmelink M, Saussez S.

Oncol Lett. 2017 Oct;14(4):4183-4189. doi: 10.3892/ol.2017.6719. Epub 2017 Aug 4.

2.

The Intraoperative Immunohistochemical Staining of CD56 and CK19 Improves Surgical Decision for Thyroid Follicular Lesions.

Pyo JY, Choi SE, Shin E, Koo J, Hong S.

J Pathol Transl Med. 2017 Sep;51(5):463-470. doi: 10.4132/jptm.2017.05.25. Epub 2017 Aug 2.

3.

Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection.

Jin Y, Liang ZY, Zhou WX, Zhou L.

J Invest Surg. 2017 Jul 31:1-8. doi: 10.1080/08941939.2017.1347218. [Epub ahead of print]

PMID:
28758812
4.
5.

Prognostic significance of preoperative and postoperative CK19 and CEA mRNA levels in peripheral blood of patients with gastric cardia cancer.

Qiao YF, Chen CG, Yue J, Ma MQ, Ma Z, Yu ZT.

World J Gastroenterol. 2017 Feb 28;23(8):1424-1433. doi: 10.3748/wjg.v23.i8.1424.

6.

Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.

Abouhashem NS, Talaat SM.

Pathol Res Pract. 2017 May;213(5):509-517. doi: 10.1016/j.prp.2017.01.017. Epub 2017 Jan 22.

PMID:
28214214
7.

EMT influences the expression of CK19 in pleural effusion-derived lung cancer cells and their invasion and metastasis.

Huang D, Xu W, Xu X, Zhang X, Zhou R, Chen P.

Oncol Lett. 2016 Dec;12(6):5052-5058. doi: 10.3892/ol.2016.5315. Epub 2016 Oct 25.

8.

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region.

Kaliszewski K, Diakowska D, Strutynska-Karpinska M, Rzeszutko M, Grzegrzolka J, Dziegiel P, Wojtczak B, Sutkowski K.

Folia Histochem Cytobiol. 2016;54(4):193-201. doi: 10.5603/FHC.a2016.0025. Epub 2017 Jan 4.

9.

Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.

Ernst J, Ikenberg K, Apel B, Schumann DM, Huber G, Studer G, Rordorf T, Riesterer O, Rössle M, Korol D, Bredell MG.

Oncotarget. 2016 Nov 15;7(46):76151-76158. doi: 10.18632/oncotarget.12691.

10.

A Pilot Study of CK19, CK20 and GCC mRNA in the Peripheral Blood as a Colorectal Cancer Biomarker Panel.

Mohammadi P, Saidijam M, Kaki A, Etemadi K, Shabab N, Yadegarazari R.

Int J Mol Cell Med. 2016 Winter;5(1):30-6.

11.

CK19 mRNA in blood can predict non-sentinel lymph node metastasis in breast cancer.

Yu XF, Yang HJ, Lei L, Wang C, Huang J.

Oncotarget. 2016 May 24;7(21):30504-10. doi: 10.18632/oncotarget.8851.

12.

CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.

Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G, Chen F, Xia H, Lv F, Zhang S, Sun L.

PLoS One. 2016 Mar 15;11(3):e0151501. doi: 10.1371/journal.pone.0151501. eCollection 2016.

13.

Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma.

Malhotra R, Urs AB, Chakravarti A, Kumar S, Gupta VK, Mahajan B.

Tumour Biol. 2016 Jul;37(7):9263-71. doi: 10.1007/s13277-016-4809-4. Epub 2016 Jan 15.

PMID:
26779624
14.

CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy.

Vieites B, López-García MÁ, Castilla C, Hernández MJ, Biscuola M, Alfaro L, Atienza MR, Castilla MÁ, Palacios J.

Histopathology. 2016 Aug;69(2):239-49. doi: 10.1111/his.12924. Epub 2016 Feb 25.

PMID:
26708058
15.

Relationship between CK19 expression, deregulation of normal keratinocyte differentiation pattern and high risk-human papilloma virus infection in oral and oropharyngeal squamous cell carcinoma.

Santoro A, Pannone G, Ninivaggi R, Petruzzi M, Santarelli A, Russo GM, Lepore S, Pietrafesa M, Laurenzana I, Leonardi R, Bucci P, Natalicchio MI, Lucchese A, Papagerakis S, Bufo P.

Infect Agent Cancer. 2015 Dec 15;10:46. doi: 10.1186/s13027-015-0041-x. eCollection 2015.

16.
17.

Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.

Dunđerović D, Lipkovski JM, Boričic I, Soldatović I, Božic V, Cvejić D, Tatić S.

Diagn Pathol. 2015 Oct 26;10:196. doi: 10.1186/s13000-015-0428-4.

18.

OSNA: A Fast Molecular Test Based on CK19 mRNA Concentration for Assessment of EBUS-TBNA Samples in Lung Cancer Patients.

Oezkan F, Khan AM, Hager T, Freitag L, Christoph D, Darwiche K.

Clin Lung Cancer. 2016 May;17(3):198-204. doi: 10.1016/j.cllc.2015.09.001. Epub 2015 Sep 21.

PMID:
26455862
19.

Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors.

Sun QF, Zhao XN, Peng CL, Hao YT, Zhao YP, Jiang N, Xue H, Guo JZ, Yun CH, Cong B, Zhao XG.

Oncol Rep. 2015 Nov;34(5):2289-95. doi: 10.3892/or.2015.4231. Epub 2015 Aug 27.

20.

Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma.

Liu Z, Yu P, Xiong Y, Zeng W, Li X, Maiaiti Y, Wang S, Song H, Shi L, Liu C, Cheng B, Zhang B, Ming J, Dong F, Ge H, Nie X, Huang T.

Int J Clin Exp Med. 2015 Mar 15;8(3):4369-74. eCollection 2015.

Supplemental Content

Support Center